Organon & Co. (OGN) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Which has higher valuation and earnings, BPMC or OGN?

Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	16.43	-$67.09M	-$2.47	-52.42
Organon & Co.	$6.40B	0.38	$864M	$2.88	3.28

Do analysts recommend BPMC or OGN?

Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.95%. Organon & Co. has a consensus target price of $18.00, suggesting a potential upside of 90.27%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.24
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Does the media favor BPMC or OGN?

In the previous week, Organon & Co. had 50 more articles in the media than Blueprint Medicines. MarketBeat recorded 58 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.15 beat Organon & Co.'s score of 0.27 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	42 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Neutral

Which has more risk & volatility, BPMC or OGN?

Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of BPMC or OGN?

77.4% of Organon & Co. shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is BPMC or OGN more profitable?

Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Organon & Co.	11.92%	227.43%	7.34%

Summary

Organon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks.